Who Paid My Doc
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Research payments
$209,665
Through program year 2024, $209,665 in research payments was reported against TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis, across 271 payments, paid by Incyte Corporation.
- Paid by
- Incyte Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $28,872 | 9 |
| 2023 | Research | $34,613 | 34 |
| 2022 | Research | $52,829 | 73 |
| 2021 | Research | $92,175 | 153 |
| 2019 | Research | $1,176 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Eric Simpson Portland, OR Named on 44 payments
- Lawrence Eichenfield San Diego, CA Named on 32 payments
- Jonathan Silverberg Washington, DC Named on 30 payments
- Leon Kircik Louisville, KY Named on 29 payments
- Andrew Blauvelt Portland, OR Named on 27 payments
- Zelma Chiesa Fuxench Philadelphia, PA Named on 11 payments
- Seth Forman Tampa, FL Named on 9 payments
- Kanwaljit Brar Denver, CO Named on 8 payments
- Linda Stein Gold W Bloomfield, MI Named on 8 payments
- Brian Kim Saint Louis, MO Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.